Auriga Partners

Type

Venture Capital

Location

Paris, France

Total investments

172

Average round size

11M

Portfolio companies

73

Rounds per year

6.88

Lead investments

17

Follow on index

0.58

Exits

35

Stages of investment
Private EquityEarly Stage VentureLate Stage Venture
Areas of investment
BiotechnologySoftwareAnalyticsInformation TechnologyHealth CareManufacturingMedical DeviceMedicalPharmaceuticalTherapeutics

Summary

Auriga Partners is the famous VC, which was founded in 1998. The venture was found in Europe in France. The main department of described VC is located in the Paris.

Among the most successful fund investment fields, there are Medical Device, Medical. Besides, a startup requires to be at the age of 11-15 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Nexthink, Ekinops, Hybrigenics. For fund there is a match between the location of its establishment and the land of its numerous investments - France. The fund has no specific favorite in a number of founders of portfolio startups. If startup sums 4 or 5+ of the founder, the chance for it to be financed is low.

The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the Auriga Partners, startups are often financed by Omnes Capital, Bpifrance, XAnge. The meaningful sponsors for the fund in investment in the same round are Sofinnova Partners, Bpifrance, 123Venture. In the next rounds fund is usually obtained by Omnes Capital, 123Venture, Wellington Partners.

The fund is constantly included in 7-12 investment rounds annually. The top amount of exits for fund were in 2017. This Auriga Partners works on 9 percentage points less the average amount of lead investments comparing to the other organizations. The real fund results show that this VC is 12 percentage points less often commits exit comparing to other companies. The important activity for fund was in 2007. The common things for fund are deals in the range of 10 - 50 millions dollars.

This organization was formed by Bernard Daugeras, Jacques Chatain, Patrick Bamas. The overall number of key employees were 8.

Show more

Investor highlights

Industry focus
Biotech/Life SciencesConsumer/RetailCybersecurityB2B/Enterprise
Stage focus
Seed
Geo focus
AlbaniaAustriaBelgiumBosnia and HerzegovinaBulgaria Show 34 more

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Analytics

Total investments
172
Lead investments
17
Exits
35
Rounds per year
6.88
Follow on index
0.58
Investments by industry
  • Biotechnology (89)
  • Health Care (62)
  • Pharmaceutical (47)
  • Manufacturing (41)
  • Medical (33)
  • Show 94 more
Investments by region
  • France (104)
  • United States (33)
  • Switzerland (13)
  • Sweden (4)
  • United Kingdom (7)
  • Show 3 more
Peak activity year
2009
Number of Unicorns
1
Number of Decacorns
1

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
19
Avg. valuation at time of investment
99M
Group Appearance index
0.74
Avg. company exit year
17
Avg. multiplicator
2.43
Strategy success index
0.80

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Alyne 27 Nov 2018 Software, Information Technology, SaaS, Security, Consulting, Risk Management Early Stage Venture 3M Munich, Bavaria, Germany
Bag Tech 01 Jul 2003 Retail, Manufacturing, Lifestyle, AgTech Early Stage Venture 2M Sialkot, Punjab, Pakistan
Evolva 11 Dec 2009 Biotechnology, Food and Beverage, Health Care, Wellness, Consulting Early Stage Venture 17M Switzerland, Aargau

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.